NRAS and neoplasm: Tumor organoids harboring KRAS, NRAS, BRAF, or PIK3CA hotspot mutations exhibited a relatively higher IC50 and area under the drug response curve (AUC) for cetuximab than organoids without hotspot mutations in these genes (Fig. 3E,F).